Press release

Fri, 17 Dec 2021 13:05:00 -0500

Fri, 17 Dec 2021 13:05:00 -0500

Novo Nordisk announces supply challenges for Wegovy® in the US

Bagsværd, Denmark, 17 December 2021 – Novo Nordisk today announced that a contract manufacturer filling syringes for Wegovy ® pens for the US market has temporarily stopped deliveries and manufacturing following issues with Good Manufacturing Practices.

As a consequence, Novo Nordisk does not expect to be able to meet demand in the US in the first half of 2022 and few new patients are expected to be able to initiate treatment. The priority for Novo Nordisk is patients who have already initiated treatment with Wegovy ®. Novo Nordisk currently expects to be able to meet demand in the US in the second half of 2022.

The supply challenges will not impact the previously communicated financial outlook for 2021. Novo Nordisk will provide the financial outlook for 2022 in connection with the announcement of the full-year 2021 results on 2 February 2022.

Conference call

On 20 December at 8.30 am CET, corresponding to 2.30 am EST, a conference call for investors will be held where members of management will elaborate on the issue. Investors will be able to listen in via a link on the investor section of

About Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).

Further information

Mette Kruse Danielsen
+45 3079 3883

Michael Bachner (US)
+1 609 664 7308

Daniel Muusmann Bohsen
+45 3075 2175

Ann Søndermølle Rendbæk
+45 3075 2253

David Heiberg Landsted
+45 3077 6915

Mark Joseph Root (US)
+1 848 213 3219